Skip to Content

REACH Study: Hydroxyurea’s 7-8 Year Impact on 600 African Children with Sickle Cell Anemia

At ASH 2023, Dr. Banu Aygun, a pediatric hematologist at Cohen Children’s Medical Center in New York, shares insights from her research on hydroxyurea’s impact on children living with sickle cell anemia in sub-Saharan Africa. The study, known as REACH (Realizing Effectiveness Across Continents with Hydroxyurea), involved 600 children across four African countries who had taken hydroxyurea for 7-8 years. Watch the MEDtalk and find out more.

Banu Aygun

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top